title: Diagnosis and determination of the clinical significance of type 1A laryngeal clefts by gelfoam injection.
abstract: Laryngeal clefts are rare congenital disorders, classified by multiple different schemes. Type IA (Armitage) and type I (Benjamin and Inglis) laryngeal clefts exhibit absence or hypoplasia of the interarytenoid muscles with an intact cricoid ring. Submucous or "occult" clefts occur with intact mucosa but absent underlying cartilage and/or muscle. Children with a diagnosis of posterior laryngeal cleft often have other congenital anomalies or medical disorders, including gastroesophageal reflux, tracheomalacia, syndrome complexes, and developmental delay. These associated disorders often confuse the diagnostic picture, as they may contribute to or account for the presenting symptoms of a laryngeal cleft. We propose a method to help clarify the clinical significance of the laryngeal clefts in these patients, and determine which patients would benefit from cleft repair. Eight patients with type IA laryngeal clefts are presented who were treated with a "test dose" Gelfoam injection into the interarytenoid area at the time of endoscopic diagnosis. All patients exhibited clinical improvement, and 4 patients showed improvement on the postinjection videofluoroscopic swallow study as compared to preoperative studies. One patient has gone on to surgical repair of the cleft after multiple injections. Endoscopic Gelfoam injection at the time of diagnosis can both alleviate symptoms and provide clarification of the posterior laryngeal cleft's contribution to the clinical status of the patient in these often complex cases.
authors.affiliation: Department of Otolaryngology, University of Minnesota, Minneapolis 55455, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Kennedy
authors.forename: M
authors.initials: M
authors.lastname: Heimbach
authors.forename: F L
authors.initials: FL
authors.lastname: Rimell
mesh_terms: D000328:Adult; D002648:Child; D003680:Deglutition Disorders / Q000150:complications / Q000175:diagnosis / Q000209:etiology; D005500:Follow-Up Studies; D005781:Gelatin Sponge, Absorbable / Q000627:therapeutic use*; D006304:Health Status; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007267:Injections; D007818:Laryngeal Diseases / Q000175:diagnosis / Q000628:therapy; D007828:Laryngoscopy; D007830:Larynx / Q000002:abnormalities*; D008297:Male; D011015:Pneumonia, Aspiration / Q000209:etiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D006490:Hemostatics